Report: Current Stock Reports

Clinical and Translational Data of RVU120 and SEL24 (MEN1703) to be presented at the 2022 American Society of Hematology (ASH) Annual Meeting
November 3, 2022

Ryvu Therapeutics presents new clinical and preclinical data for RVU120 program at 34th AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium
October 26, 2022

Posters to be presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium
October 12, 2022

Adoption by the Company’s Management Board of a resolution on issuance of shares within the framework of authorized capital and conclusion of lock-up agreements
October 5, 2022

Registration of an amendment to the Company’s Articles of Association
October 3, 2022

Shareholders controlling at least 5% of the votes at the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A. convened on September 19th, 2022
September 19, 2022

Resolutions adopted by the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
September 19, 2022

Self-correction to the draft resolution of the General Meeting of Ryvu Therapeutics S.A. convened for September 19, 2022
September 14, 2022

Convening of the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
August 19, 2022

Ryvu Therapeutics’ development plans for 2022-2024
August 19, 2022